Recruiting

Testing a shingles vaccine in people with HIV and healthy adults

Plain-English translation of NCT05580458 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This clinical trial is testing , a vaccine designed to prevent shingles (a painful viral infection). The study will give the medication to people living with HIV—divided into two groups based on their immune strength—and to healthy adults aged 50 and older. Researchers want to see how well the vaccine works and whether it is safe in these different populations.

Shingles is a serious concern for people with weakened immune systems, but it's unclear how well this particular vaccine works for people living with HIV compared to people without HIV. This study will help doctors understand whether this treatment can safely protect these vulnerable groups from shingles.

Do you qualify?

You likely qualify if…

you are at least 18 years old (if you have HIV) or at least 50 years old (if you are a healthy volunteer)
you have HIV and have had an undetectable viral load for at least the past 3 months
you have been on a stable HIV treatment regimen for at least 6 months, or you are an elite controller managing HIV without medications
you do not have any active, uncontrolled infections or illnesses
you are willing to use contraception from screening through month 3 if you could become pregnant
you have a primary care provider

You likely don't qualify if…

you have previously received Shingrix or received Zostavax (an older shingles vaccine) within the past 12 months
you have a severe allergy to any ingredient in Shingrix
you have had shingles or chickenpox symptoms within the past month
you are pregnant, breastfeeding, or planning to become pregnant during the study
you have received any other investigational vaccine or live virus vaccine within the past 30 days

What participation looks like

You will receive two doses of the medication, given as injections about 2 months apart. You will have study visits at the time of each dose and at follow-up visits 3 and 12 months after your first dose. At each visit, blood will be drawn to check your immune response and monitor for any side effects. You will also be asked about any health changes or reactions you experience, making this a one-year commitment overall.

Testing a shingles vaccine in people with HIV and healthy adults

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)